

AMENDMENTS TO THE CLAIMS

1.-56. (Canceled)

57. (Currently amended) ~~An isolated antibody~~ Isolated antibodies that specifically bind[[s]] a protein comprising the amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:4, ~~an amino acid sequence having at least 95% identity to the amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:4, or a protein encoded by a nucleotide sequence that hybridizes to the polynucleotide of SEQ ID NO: 4 under high stringency conditions.~~

58. (Currently amended) The isolated antibodies ~~antibody~~ according to Claim 57, wherein said antibodies ~~antibody~~ is a monoclonal antibodies ~~antibody~~.

59. (Currently amended) The isolated antibodies ~~antibody~~ according to Claim 57, wherein said antibodies ~~antibody~~ is ~~a~~ are polyclonal antibodies ~~antibody~~.

60. (Currently amended) The isolated antibodies ~~antibody~~ according to Claim 57, wherein said antibodies ~~antibody~~ is ~~a~~ are synthetic antibodies ~~antibody~~.

61. (Currently amended) The isolated antibodies ~~antibody~~ according to Claim 60, wherein said antibodies ~~antibody~~ is ~~a~~ are Fab fragments.

62. (Withdrawn- Currently amended) A method of diagnosing or monitoring a disease condition in a mammal, which disease condition is characterized by DEC-205 SV and/or DCL-1 expression, said method comprising:

obtaining a biological sample from said mammal; and

screening said sample with antibodies ~~an antibody~~ according to Claim 57.

63. (Withdrawn) The method of Claim 62, wherein said disease condition is Hodgkin's lymphoma.

64. (Withdrawn) The method of Claim 62, wherein said sample is a tissue section.

65. (Withdrawn) The method of Claim 62, wherein the screening step is performed by a procedure selected from the group consisting of Western blotting, ELISA, and flow cytometry.